



INTERNATIONAL SPEAKER TOUR

# BEYOND BOUNDARIES

**Rethinking OAB Treatments from the Bladder to Brain**

Mitigating Cognitive Risks in Overactive Bladder (OAB)  
Treatment for Patient-Centred Care

EDUCATIONAL  
ACTIVITIES

**1.5**  
HOURS

Date

**Tuesday  
27<sup>th</sup> August 2024**

Time

**6:45pm–8:30pm**

Location

**Victoria Park  
Function Centre,  
Herston, QLD, 4006**

Dear Doctor {{accFname}} {{accLname}},  
{{customText()}}

**Join Dr. Adrian Wagg and Dr. Joseph Schoeman for an  
exclusive event focused on alternative therapeutic  
strategies to address tolerability and potential  
discomfort in your patients living with OAB symptoms.**

With a dedicated focus on shared decision-making and patient education, participate in discussions navigating the substantial cognitive burden linked with anticholinergics in OAB management. Together, we will explore practical considerations geared towards bolstering adherence and persistence to treatment, all with the overarching goal of improving patient outcomes and enriching their quality of life.

This event is suitable for the self-reporting of 1.5 hours of Educational Activity in the RACGP CPD Program for the 2023-25 triennium.

**REGISTER  
TODAY!**



To register your  
interest, scan the  
QR code or visit

[www.beyondboundariesoab.com.au](http://www.beyondboundariesoab.com.au)



**DR. ADRIAN WAGG**

Dr. Adrian Wagg is a specialist in Geriatric and General Internal Medicine with expertise in health services research. He

EDUCATIONAL  
ACTIVITIES

**1.5**  
HOURS



**DR. JOSEPH SCHOEMAN**

Dr. Joseph Schoeman is a general urologist who offers a holistic general service in urology with a particular focus

is currently a Professor in the Department of Medicine at the University of Alberta and an Associated Professor of Continence Sciences at the University of Gothenburg, Sweden.

on incontinence in both male and female patients. He is also a part of the Pelvic Medicine Centre, a new venture at the St Andrews War Memorial Hospital.

## LEARNING OUTCOMES

1. Outline the potential for anticholinergic burden accumulation with prolonged use or multiple prescriptions for OAB.
2. Summarise the research linking Anticholinergic Cognitive Burden (ACB) from medications used in OAB treatment, particularly in elderly populations.
3. Apply appropriate cognitive assessment methods to identify potential cognitive decline in patients undergoing OAB treatment.
4. Discuss non-anticholinergic options for managing OAB, including beta-3 agonists and behavioural interventions.
5. Facilitate shared decision-making regarding treatment options, emphasising potential cognitive effects.

Registration	6:45pm–7:00pm
Presentations	7:00pm–8:00pm
Discussion	8:00pm–8:20pm
Conclusion	8:20pm–8:30pm

## REGISTER TODAY!

For a detailed agenda,  
scan the QR code or visit

[www.beyondboundariesoab.com.au](http://www.beyondboundariesoab.com.au)



Warm regards,

{{userPhoto}}

{{userName}}  
{{User.Title}}

Astellas Pharma Australia Pty Ltd  
Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113  
Mobile: {{User.MobilePhone}}  
Email: {{userEmailAddress}}

**Abbreviations:** LUTS, lower urinary tract symptom; OAB, overactive bladder.

Astellas Australia's privacy policy, available on our website at <https://www.astellas.com/au/privacy-policy> contains more information about how we deal with personal information, your right to access and correct your information and our privacy complaint process. The information in this email is confidential, is intended for the addressed recipient only and must not be copied, distributed or disclosed.

Any subsequent action taken with this email, including forwarding is not the responsibility of Astellas or its affiliates. If you are not the intended recipient of this email, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this email is strictly prohibited and may be unlawful.

You have received this email because you indicated that you are willing to receive occasional emails based on your preferences. If you do not wish to receive such emails in the future, you may email: [register@beyondboundariesoab.com.au](mailto:register@beyondboundariesoab.com.au)

Astellas Pharma Australia Pty Ltd, ABN 81 147 915 482.  
Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113.  
Date of preparation: July 2024. MAT-AU-BET-2024-00022. #10515A.

